EMA Authorised: Javlor (vinflunine) — Pierre Fabre Medicament

View source ↗

Summary

The European Medicines Agency authorised Javlor (vinflunine) from Pierre Fabre Medicament for transitional cell carcinoma of the urothelium (urothelial carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Javlor (vinflunine)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Transitional Cell;Urologic Neoplasms. MAH: Pierre Fabre Medicament. Decision date: 16/07/2025